ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Patients Respond to Oral BRAF Inhibitor

by Dennis H. Kraus, MD, and Luc Morris, MD • April 4, 2011

  • Tweet
  • Email
Print-Friendly Version

In patients with stage IV melanoma with distant metastases, what is the response rate to an oral inhibitor of the protein kinase BRAF?

You Might Also Like

  • Survival Rates Comparable in Children and Adults with Oral Tongue Squamous Cell Cancer
  • Similar Genetic Signature Associated with More Aggressive Oral Cancer found in Humans and Mice
  • How to Respond When Patients Ask about Vaccines
  • First Two Patients Respond to Gene Therapy in Melanoma Study
Explore This Issue
April 2011

Background: There are few effective therapies for patients with stage IV metastatic melanoma. Response rates to standard therapy (interleukin-2 or dacarbazine) are 10 to 20 percent, and complete responses are exceedingly rare. The activating V600E mutation in the BRAF gene is found in 40 to 60 percent of melanomas. The oral agent PLX4032 is a potent inhibitor of mutated BRAF signaling.

Study design: Phase I dose-escalation trial followed by extension phase. The dose-escalation phase included 55 patients. The recommended phase II dose was then administered to 32 patients with metastatic melanoma testing positive for the V600E mutation in the BRAF gene.

Setting: Multi-center trial.

Synopsis: An oral dose of 960 mg twice daily was selected as the recommended phase II dose. The most common toxicities were rash, arthralgia, nausea, photosensitivity, cutaneous squamous cell carcinoma and pruritus, 89 percent of which were grade 1-2. Cutaneous squamous cell carcinomas developed in 31 percent of patients; these were resected and did not lead to treatment discontinuation.

Response rate in the extension cohort of V600E mutant melanomas was 26 of 32 patients (81 percent). Dramatic tumor responses were observed in the lungs, lymph nodes, visceral organs and bone metastases. The median progression-free survival was greater than seven months, and median overall survival had not been reached at the time of data analysis.

Bottom line: An unprecedented 81 percent response rate was observed in patients with metastatic melanoma carrying a mutated, activated BRAF gene and treated with an oral BRAF inhibitor. This mutation is found in 40 to 60 percent of melanomas, a similar percentage of papillary and anaplastic thyroid cancers and a smaller percentage of other cancers. A phase III trial is currently underway to determine whether PLX4032 improves overall survival.

Citation: Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New Engl J Med. 2010;363(9):809-819.

—Reviewed by Dennis H. Kraus, MD, and Luc Morris, MD

Filed Under: Clinical, Laryngology, Literature Reviews Tagged With: BRAF, clinical, Oral BRAF Inhibitor, patient response, response rate, stage IV melanomaIssue: April 2011

You Might Also Like:

  • Survival Rates Comparable in Children and Adults with Oral Tongue Squamous Cell Cancer
  • Similar Genetic Signature Associated with More Aggressive Oral Cancer found in Humans and Mice
  • How to Respond When Patients Ask about Vaccines
  • First Two Patients Respond to Gene Therapy in Melanoma Study

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Otolaryngologists Have a Major Role to Play in Treating COVID-19 Long-Haulers
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.